694 related articles for article (PubMed ID: 25302401)
1. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of novel anticancer ruthenium-arene pyridinylmethylene scaffolds via three-component reaction.
Jadhav GR; Sinha S; Chhabra M; Paira P
Bioorg Med Chem Lett; 2016 Jun; 26(11):2695-700. PubMed ID: 27090558
[TBL] [Abstract][Full Text] [Related]
3. Phenanthroline ligands are biologically more active than their corresponding ruthenium(II) arene complexes.
Valladolid J; Hortigüela C; Busto N; Espino G; Rodríguez AM; Leal JM; Jalón FA; Manzano BR; Carbayo A; García B
Dalton Trans; 2014 Feb; 43(6):2629-45. PubMed ID: 24327227
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity and DNA binding of a bifunctional Ru(II) arene aqua-complex with the 2,4-diamino-6-(2-pyridyl)-1,3,5-triazine ligand.
Busto N; Valladolid J; Martínez-Alonso M; Lozano HJ; Jalón FA; Manzano BR; Rodríguez AM; Carrión MC; Biver T; Leal JM; Espino G; García B
Inorg Chem; 2013 Sep; 52(17):9962-74. PubMed ID: 23957818
[TBL] [Abstract][Full Text] [Related]
5. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
6. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands.
Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F
Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875
[TBL] [Abstract][Full Text] [Related]
7. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
8. Antimalarial activity of ruthenium(II) and osmium(II) arene complexes with mono- and bidentate chloroquine analogue ligands.
Ekengard E; Glans L; Cassells I; Fogeron T; Govender P; Stringer T; Chellan P; Lisensky GC; Hersh WH; Doverbratt I; Lidin S; de Kock C; Smith PJ; Smith GS; Nordlander E
Dalton Trans; 2015 Nov; 44(44):19314-29. PubMed ID: 26491831
[TBL] [Abstract][Full Text] [Related]
9. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
10. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage.
Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B
Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276
[TBL] [Abstract][Full Text] [Related]
11. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
[TBL] [Abstract][Full Text] [Related]
13. Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time.
Rafols L; Josa D; Aguilà D; Barrios LA; Roubeau O; Cirera J; Soto-Cerrato V; Pérez-Tomás R; Martínez M; Grabulosa A; Gamez P
Inorg Chem; 2021 Jun; 60(11):7974-7990. PubMed ID: 33979132
[TBL] [Abstract][Full Text] [Related]
14. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
15. Picolinate ruthenium(II)-arene complex with in vitro antiproliferative and antimetastatic properties: comparison to a series of ruthenium(II)-arene complexes with similar structure.
Gligorijević N; Aranđelović S; Filipović L; Jakovljević K; Janković R; Grgurić-Šipka S; Ivanović I; Radulović S; Tešić ZLj
J Inorg Biochem; 2012 Mar; 108():53-61. PubMed ID: 22266461
[TBL] [Abstract][Full Text] [Related]
16. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies.
He L; Liao SY; Tan CP; Ye RR; Xu YW; Zhao M; Ji LN; Mao ZW
Chemistry; 2013 Sep; 19(36):12152-60. PubMed ID: 23878093
[TBL] [Abstract][Full Text] [Related]
19. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes.
Lari M; Martínez-Alonso M; Busto N; Manzano BR; Rodríguez AM; Acuña MI; Domínguez F; Albasanz JL; Leal JM; Espino G; García B
Inorg Chem; 2018 Nov; 57(22):14322-14336. PubMed ID: 30379535
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
